All posts

Follow Us

LinkedInInstagramX
Quarterly ResultsArchiveLast updated 22 November 20263 min read

Modern Diagnostic (MDRC) Q2 FY27 Profit Collapses 80% as Expansion Costs Bite

The diagnostic chain's revenue held steady, but a surge in expenses from new labs and higher interest wiped out nearly all profitability.

By Abhinav Swaroop, CFA, Chief Business Officer: Hexawealth · Created 22 November 2026

Modern Diagnostic & Research Centre's Q2 FY27 saw revenue inch up 1.6% year-on-year to ₹43.87 crore. However, net profit plunged 80.4% to just ₹0.62 crore as expansion-related costs soared and other income dried up.

For a regional diagnostic chain spending to grow, the test is whether new centres fill fast enough to cover their upfront costs. Modern Diagnostic’s September quarter shows that balance tipping the wrong way. Revenue was nearly flat, but profit collapsed under the weight of its own expansion.

The numbers tell a story of top-line stagnation and a brutal margin squeeze. Revenue of ₹43.87 crore was up a mere 1.6% from a year ago. Net profit, however, cratered 80.4% to ₹0.62 crore. The net profit margin shrank to 1.4%, down 590 basis points year-on-year.

Revenue & profit

Revenue (₹ Cr)

Profit (₹ Cr)

Revenue & profitQ2 FY26 (Sep 2025) 43.19, Q4 FY26 (Mar 2026) 39.92, Q2 FY27 (Sep 2026) 43.87. Q2 FY26 (Sep 2025) 3.17, Q4 FY26 (Mar 2026) 2.08, Q2 FY27 (Sep 2026) 0.62020406080Q2 FY26 (Sep 2025)Q4 FY26 (Mar 2026)Q2 FY27 (Sep 2026)
  • Revenue (₹ Cr), Q2 FY26 (Sep 2025): 43.19
  • Revenue (₹ Cr), Q4 FY26 (Mar 2026): 39.92
  • Revenue (₹ Cr), Q2 FY27 (Sep 2026): 43.87
  • Profit (₹ Cr), Q2 FY26 (Sep 2025): 3.17
  • Profit (₹ Cr), Q4 FY26 (Mar 2026): 2.08
  • Profit (₹ Cr), Q2 FY27 (Sep 2026): 0.62

Revenue (₹ Cr)

Revenue (₹ Cr)Q2 FY26 (Sep 2025) 43.19, Q4 FY26 (Mar 2026) 39.92, Q2 FY27 (Sep 2026) 43.87020406080Q2 FY26 (Sep 2025)Q4 FY26 (Mar 2026)Q2 FY27 (Sep 2026)
  • Revenue (₹ Cr), Q2 FY26 (Sep 2025): 43.19
  • Revenue (₹ Cr), Q4 FY26 (Mar 2026): 39.92
  • Revenue (₹ Cr), Q2 FY27 (Sep 2026): 43.87

Profit (₹ Cr)

Profit (₹ Cr)Q2 FY26 (Sep 2025) 3.17, Q4 FY26 (Mar 2026) 2.08, Q2 FY27 (Sep 2026) 0.6201234Q2 FY26 (Sep 2025)Q4 FY26 (Mar 2026)Q2 FY27 (Sep 2026)
  • Profit (₹ Cr), Q2 FY26 (Sep 2025): 3.17
  • Profit (₹ Cr), Q4 FY26 (Mar 2026): 2.08
  • Profit (₹ Cr), Q2 FY27 (Sep 2026): 0.62

Net Profit Margin (%)

Net Profit Margin (%)Q2 FY26 (Sep 2025) 7.3, Q4 FY26 (Mar 2026) 5.2, Q2 FY27 (Sep 2026) 1.40%5%10%15%20%Q2 '26Q4 '26Q2 '27
  • Net Profit Margin (%), Q2 FY26 (Sep 2025): 7.3
  • Net Profit Margin (%), Q4 FY26 (Mar 2026): 5.2
  • Net Profit Margin (%), Q2 FY27 (Sep 2026): 1.4
MetricCurrentQ2 FY27 (Sep 2026)PreviousQ4 FY26 (Mar 2026)
Revenue (₹ Cr)
43.87
39.92
Profit (₹ Cr)
0.62
2.08
Net Profit Margin (%)
1.4
5.2

Why the bottom line vanished

A 11.2% year-on-year jump in total expenses was the primary culprit. Research from mcapital.in points to staff, rent and ramp-up costs at new laboratories in Gurugram, East Delhi, Meerut and Mohali. Depreciation also rose 17.4%, a direct hit from ₹5.53 crore of equipment spent in the quarter.

At the same time, a crucial cushion vanished. Other income plunged 83.6% to just ₹0.10 crore. This removed a support that had previously helped offset operating costs, making the expense surge far more painful for the bottom line.

The debt and expansion drag

Higher interest costs, up 18.4% year-on-year, added to the pressure. This reflects increased borrowings, which stood at ₹37.1 crore at the end of FY26 according to newboard.in. The company is spending ahead of revenue, funding a network it expects to grow from 25 to about 30 centres.

Live Chart

· MDRC

(BSE)

ISIN: INE1HK501016

Management is considering an acquisition of a diagnostic centre with imaging facilities, but no terms were disclosed. The immediate outlook, however, is for continued strain. mcapital.in estimates suggest the full-year net profit could be 70-90% below the ₹5.25 crore reported in FY26.

Key Points

  • Revenue growth stalled at 1.6% year-on-year, indicating new centres are not yet driving volume.
  • Net profit margin collapsed to 1.4% due to surging operational costs and much lower other income.
  • Higher depreciation and interest expenses reflect heavy capital spending and increased borrowings for expansion.
  • The full-year earnings trajectory points to a severe compression, with profitability unlikely to recover until new centres ramp up.

Hexa Perspective

This quarter lays bare the execution risk in Modern Diagnostic’s expansion. The model is working in reverse: costs are arriving today, while the revenue payoff is deferred. The 590-basis-point margin contraction is severe, and with a large part of its IPO capex still to be spent, the depreciation drag has room to run.

The path back requires new centres to fill rapidly, turning fixed costs into operating leverage. Until patient volumes catch up to the expanded footprint, the company will be spending to stand still. Investors are left weighing whether this is a temporary trough in an investment cycle or a sign that growth is becoming prohibitively expensive.

Share or follow HexaWealth

Also read

Want this applied to your portfolio?

Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.

Modern Diagnostic & Research Centre (MDRC) Q2 FY27 results, revenue and profits.

Frequently asked questions

What were Modern Diagnostic's Q2 FY27 results?
Modern Diagnostic & Research Centre reported Q2 FY27 revenue of ₹43.87 crore, a slight 1.6% increase year-on-year. Net profit for the quarter plunged 80.4% to ₹0.62 crore, as a surge in operational costs from new lab expansions severely compressed margins.
Why did Modern Diagnostic's Q2 FY27 profit drop?
Modern Diagnostic's Q2 FY27 profit fell 80.4% primarily due to a 11.2% surge in total expenses from new centre openings and a 83.6% decline in other income. Higher depreciation on new equipment and increased interest costs also contributed to the sharp drop in profitability.
What was Modern Diagnostic's net profit margin in Q2 FY27?
Modern Diagnostic's net profit margin was 1.4% in Q2 FY27, a steep decline of 590 basis points from the 7.3% margin in the same quarter last year. The collapse was driven by rising costs that far outpaced minimal revenue growth.
Why did Modern Diagnostic's total expenses surge in Q2 FY27?
Modern Diagnostic's total expenses rose over 11% year-on-year due to staff, rent and ramp-up costs associated with launching new laboratories in Gurugram, East Delhi, Meerut, and Mohali, as noted in analysis by mcapital.in.
What caused the sharp decline in Modern Diagnostic's other income?
Modern Diagnostic's other income fell 83.6% year-on-year to ₹0.10 crore in Q2 FY27. This significant drop removed a financial cushion that had previously helped offset operational expenses, exacerbating the profit decline.
What drove the increase in depreciation for Modern Diagnostic?
Depreciation rose 17.4% year-on-year for Modern Diagnostic in Q2 FY27 due to capital expenditure on new medical equipment. Analysis by mcapital.in indicates ₹5.53 crore was spent on equipment in the quarter, leading to higher depreciation charges.
Why did Modern Diagnostic's interest cost increase year-on-year?
Modern Diagnostic's interest cost increased 18.4% year-on-year in Q2 FY27, reflecting higher borrowings used to fund its expansion. The company's borrowings stood at ₹37.1 crore at the end of FY26, up significantly from the prior year.
What is the status of Modern Diagnostic's network expansion?
Modern Diagnostic is actively expanding, having recently launched labs in Gurugram, East Delhi, Meerut, and Mohali. Work on centres in Aligarh and Lucknow is nearly complete, with the goal of reaching about 30 centres by year-end from 25.
Modern Diagnostic & Research Centre Q2 profit drop
Modern Diagnostic & Research Centre's Q2 FY27 net profit dropped 80.4% to ₹0.62 crore. The severe decline was caused by a combination of flat revenue growth and a sharp rise in expenses linked to the company's laboratory expansion program.
Modern Diagnostic Q2 FY27 results November 2026
Modern Diagnostic announced its Q2 FY27 results on 14 November 2026. The company reported revenue of ₹43.87 crore and a net profit of ₹0.62 crore for the quarter ended September 2026, representing a major profit contraction from the previous year.